Condition: Diffuse Low Grade B-Cell Lymphoma · Primary Mediastinal Large B-cell Lymphoma (PMBCL) · Mantle Cell Lymphoma · Sponsor: Paolo Corradini
The goal of this observational study on chimeric antigen receptor T-cell therapy is to monitor the feasibility, efficacy, toxicity and biomarkers in a real life setting. Partecipants will be asked to agree to their clinical data collection and to partecipate to the optional biological study that aims to evaluate biomarkers of toxicity and response (clinical characteristics, cytokine profile, cellcomposition and type of the CAR-T cell product, lymphoma genomics). The study will evaluate even the disease response according to lugano criteria by PET and CT in routine clinical activity.
This description comes directly from the study's public registry record.
Paolo Corradini, Professor · +39 02 2390 2950 · paolo.corradini@istitutotumori.mi.it
Anisa Bermema, PhD · +39 02 2390 3146 · anisa.bermema@istitutotumori.mi.it
Always discuss trial participation with your own doctor first.
| Fondazione IRCCS Istituto Nazionale Tumori | Milan, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06339255